Get informed when a big investor buys or sells
+ FollowOctober 27, 2026 - AI Summary
Overvalued by 25.9% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $74.08 Billion |
|---|---|
| Enterprise Value | $-212,561,110,877.00 |
| Annual dividend | $1.34 |
| Dividend yield | 2.97% |
| Earnings per Share | $263.96 |
| Beta | 0.55 |
| Outstanding Shares | 1,645,303,000 |
| P/E Ratio | 23.46 |
|---|---|
| PEG | 86.06 |
| Price to Sales | 0.05 |
| Price to Book Ratio | 0.03 |
| Enterprise Value to Revenue | -0.15 |
| Enterprise Value to EBIT | -0.31 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | -0.45 |
| Debt to Equity | 0.05 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese ...